Spotlight on Psychiatry

Credits: 0.50 CME
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD
Marwan Sabbagh, MD
Postgraduate Institute for Medicine

From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
  2. Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
  2. Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Psychiatry Presentations

0.50 CME
Postgraduate Institute for Medicine
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 3: Tools for Diagnostic and Monitoring Strategies in the Future Management of AD

From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 3: Tools for Diagnostic and Monitoring Strategies in the Future Management of AD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

Recognize the role of existing and emerging biomarkers in the categorization and monitoring of AD and use this information to identify how this could be implemented in future AD management should such tools become more accessible.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 3 will focus on the role of biomarkers in AD diagnosis and monitoring as well as the expanded need for these methods should a disease-specific therapy be approved.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the third of this three-part series, Drs. Sabbagh, Smith, and Isaacson will outline the biomarkers that they currently use in AD management alongside their projected changes to standard clinical practices should disease-specific therapies become available. They will also discuss the emergence of novel serum biomarker tests and the potential importance they may develop in the coming years.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

Recognize the role of existing and emerging biomarkers in the categorization and monitoring of AD and use this information to identify how this could be implemented in future AD management should such tools become more accessible.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 3 will focus on the role of biomarkers in AD diagnosis and monitoring as well as the expanded need for these methods should a disease-specific therapy be approved.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the third of this three-part series, Drs. Sabbagh, Smith, and Isaacson will outline the biomarkers that they currently use in AD management alongside their projected changes to standard clinical practices should disease-specific therapies become available. They will also discuss the emergence of novel serum biomarker tests and the potential importance they may develop in the coming years.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

0.75 CME
Postgraduate Institute for Medicine
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 2: Current Treatments and Rising Phase 3 Disease-Modifying Therapies

From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 2: Current Treatments and Rising Phase 3 Disease-Modifying Therapies

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
45 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
  2. Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
45 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
  2. Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

0.50 CME
Postgraduate Institute for Medicine
From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD

From Critique to Consensus: Quantifying and Clarifying Expert Perspectives on the Future Management of Alzheimer’s Disease (AD) – Part 1: Evolving Understanding of Pathophysiology and Proposed Framework of AD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
  2. Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: February 4, 2021
Expires: February 4, 2022
30 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

  1. Assess the fundamental principles and current status of the amyloid hypothesis—including historical obstacles associated with evaluating amyloid targeting disease modifying therapies (DMTs)—to appraise its potential utility and limitations in guiding AD diagnostic and clinical strategy.
  2. Identify the potential utility of a biomarker-based approach to AD management in order to understand how such strategies may be integrated into practice in the event that targeted therapies become available.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 1 will focus on the way our understanding of AD pathophysiology has evolved and the most widely held viewpoints among modern dementia specialists.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the first of this three-part series, Drs. Sabbagh, Smith, and Isaacson will review the traditional theories of the path to AD as well as their own personal takes on modern advancements in its understanding. They will also discuss how the historical mystery of AD has contributed to the widespread failures in pharmaceutical development and why these failures may provide more insight than may be apparent at the surface.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.


Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis


Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.


Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

0.50 CME / MOC
Vindico
Incorporating Evidence-based Approaches in ADHD: A Wheel of Knowledge Challenge

Incorporating Evidence-based Approaches in ADHD: A Wheel of Knowledge Challenge

Start

Activity Details

Free CME/MOC
0.50 AMA PRA Category 1 Credit(s)™/ABIM MOC/ABP MOC Part 2/AAFP Prescribed Credit
Released: December 31, 2020
Expires: December 30, 2021
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family practice physicians, pediatricians, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with attention-deficit/hyperactivity disorder (ADHD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the impact of ADHD symptoms on functional abilities and quality of life.
  • Apply standardized assessment tools and diagnostic recommendations to identify patients with ADHD and monitor treatment effects.
  • Incorporate clinical evidence regarding efficacy and safety to select among available therapy options for patients with ADHD.
  • Develop individualized treatment plans for ADHD based on evidence-based approaches and patient characteristics.

Activity Description

Attention-deficit/hyperactivity disorder is the most common behavioral disorder in children and affects 2.5% to 5% of adults in the United States. The prevalence of ADHD in children and adolescents continues to increase. In adults, ADHD is often a continuation of symptoms that were not diagnosed in childhood, and thus is often underrecognized and undiagnosed. Clinicians are challenged to accurately diagnose and manage ADHD based on individual patient characteristics. In this Wheel of Knowledge challenge, your intellect will be tested on the latest updates in diagnosing and treating ADHD.

Activity Chair

Oren W. Mason, MD
Founder and Director
Attention MD
Grand Rapids, MI

Disclosure:
Royalty: Lulu Press
Consulting Fee: Eisai, Sunovion

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Larry Culpepper, MD, MPH, FAAFP
Disclosure:
Royalty: Oxford University Press, UpToDate
Consulting Fee: AbbVie, Acadia, Allergan, Eisai, Merck, Takeda
Ownership Interest: M3 Information
Physicians Postgraduate Press: Editor in Chief of the Primary Care Companion for CNS Diseases

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and

  • 0.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

The AAFP has reviewed Incorporating Evidence-based Approaches in ADHD: A Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 12/31/2020 to 12/30/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 0.5 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.50 AMA PRA Category 1 Credit(s)™/ABIM MOC/ABP MOC Part 2/AAFP Prescribed Credit
Released: December 31, 2020
Expires: December 30, 2021
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family practice physicians, pediatricians, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with attention-deficit/hyperactivity disorder (ADHD).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the impact of ADHD symptoms on functional abilities and quality of life.
  • Apply standardized assessment tools and diagnostic recommendations to identify patients with ADHD and monitor treatment effects.
  • Incorporate clinical evidence regarding efficacy and safety to select among available therapy options for patients with ADHD.
  • Develop individualized treatment plans for ADHD based on evidence-based approaches and patient characteristics.

Activity Description

Attention-deficit/hyperactivity disorder is the most common behavioral disorder in children and affects 2.5% to 5% of adults in the United States. The prevalence of ADHD in children and adolescents continues to increase. In adults, ADHD is often a continuation of symptoms that were not diagnosed in childhood, and thus is often underrecognized and undiagnosed. Clinicians are challenged to accurately diagnose and manage ADHD based on individual patient characteristics. In this Wheel of Knowledge challenge, your intellect will be tested on the latest updates in diagnosing and treating ADHD.

Activity Chair

Oren W. Mason, MD
Founder and Director
Attention MD
Grand Rapids, MI

Disclosure:
Royalty: Lulu Press
Consulting Fee: Eisai, Sunovion

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Larry Culpepper, MD, MPH, FAAFP
Disclosure:
Royalty: Oxford University Press, UpToDate
Consulting Fee: AbbVie, Acadia, Allergan, Eisai, Merck, Takeda
Ownership Interest: M3 Information
Physicians Postgraduate Press: Editor in Chief of the Primary Care Companion for CNS Diseases

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and

  • 0.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

The AAFP has reviewed Incorporating Evidence-based Approaches in ADHD: A Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 12/31/2020 to 12/30/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 0.5 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com